Researchers have discovered a way to program cells to inhibit CRISPR-Cas9 activity. “Anti-CRISPR” proteins had previously been isolated from viruses that infect bacteria, but now University of Toronto and University of Massachusetts Medical School scientists report three families of proteins that turn off CRISPR systems specifically used for gene editing. The work, which appears December 15 in Cell, offers a new strategy to prevent CRISPR-Cas9 technology from making unwanted changes.
“Making CRISPR controllable allows you to have more layers of control on the system and to turn it on or off under certain conditions, such as where it works within a cell or at what point in time,” says lead author Alan Davidson, a phage biologist and bacteriologist at the University of Toronto. “The three anti-CRISPR proteins we’ve isolated seem to bind to different parts of the Cas9, and there are surely more out there.”
CRISPR inhibitors are a natural byproduct of the evolutionary arms race between viruses and bacteria. Bacteria use CRISPR-Cas complexes to target and cut up genetic material from invading viruses. In response, viruses have developed proteins that, upon infection, can quickly bind to a host bacterium’s CRISPR-Cas systems, thus nullifying their effects.
Anti-CRISPR proteins are attractive experimentally because they offer one solution for preventing potential off-target effects. Research in mice has shown that such mistakes may be rare when using CRISPR-Cas9 technology, but even the occasional error could be a serious problem when being used therapeutically in humans.
“CRISPR-Cas9 in ancillary cells, tissues, or organs is at best useless and at worst a safety risk,” says co-author and collaborator Erik J. Sontheimer, a professor in the RNA Therapeutics Institute at the University of Massachusetts Medical School. “But if you could build an off-switch that keeps Cas9 inactive everywhere except the intended target tissue, then the tissue specificity will be improved.”
“Knowing we have a safety valve will allow people to develop many more uses for CRISPR,” says co-author Karen Maxwell, an assistant professor in biochemistry who is also at the University of Toronto. “Things that may have been too risky previously might be possible now.”
While the work will be of great interest to those studying gene editing and gene drives, Davidson’s team is also curious to follow up on the biology of how bacterial CRISPRs and viral anti-CRISPRs interact.
“We didn’t set out to find anti-CRISPRs, we were just trying to understand how phages incorporate themselves into bacterial genomes and stumbled onto something that I think will be important for biotechnology,” Davidson says.
“We were being observant and following a path that we didn’t know where it could lead, and it’s just been a very fun and exciting story.”
Learn more: An anti-CRISPR for gene editing
[osd_subscribe categories=’crispr’ placeholder=’Email Address’ button_text=’Subscribe Now for any new posts on the topic “CRISPR”‘]
Receive an email update when we add a new CRISPR article.
The Latest on: Anti-CRISPR
[google_news title=”” keyword=”anti-CRISPR” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Anti-CRISPR
- ‘Real Americans’ is a sweeping novel with an eye for detailon April 30, 2024 at 6:51 am
Rachel Khong follows up “Goodbye, Vitamin” with the tale of three generations of people grappling with identity.
- T-Cell Exhaustion in CLL: Allogeneic CAR T Trial Reaching Patients With Unmet Needon April 29, 2024 at 5:59 pm
"Off the shelf" CAR T-cell therapies could offer a solution in chronic lymphocytic leukemia, where T-cell exhaustion creates treatment challenges. This article will appear in the May 2024 issue of ...
- CRISPR-Cas Gene Editing Help Combat Antimicrobial Resistanceon April 29, 2024 at 11:06 am
Despite rising global antimicrobial resistance (AMR), researchers highlight CRISPR/Cas systems' potential in antimicrobial agent development.
- Philips Posts Record Surge After US Sleep Apnea Settlementon April 29, 2024 at 3:46 am
Royal Philips NV shares soared by a record after a lower-than-expected settlement on US claims linked to faulty sleep apnea devices, stoking hopes the manufacturer has moved past concerns that have ...
- Can CRISPR-Cas gene editing tech fight antimicrobial resistance?on April 28, 2024 at 11:18 am
CRISPR-Cas, the Nobel Prize-winning gene-editing technology, has the potential to target resistance genes and make bacteria sensitive to first-line antibiotics again, according to a study.
- Experts develop way to harness CRISPR technology to deal with antimicrobial resistanceon April 26, 2024 at 3:10 pm
Antimicrobial resistance (AMR) is continuing to increase globally, with rates of AMR in most pathogens increasing and threatening a future in which every day medical procedures may no longer be ...
- CRISPR is promising to tackle antimicrobial resistance, but bacteria can fight backon April 26, 2024 at 3:00 pm
In his presentation "How to use CRISPR-Cas to combat AMR" at the ESCMID Global Congress, Assistant Prof. Ibrahim Bitar, Department of Microbiology, Faculty of Medicine and University Hospital in Plzen ...
- MIT Technology Reviewon April 26, 2024 at 3:00 am
But when I unboxed my two petunias this week, they were in bad shape, with rotted leaves. And in a day, they were dead crisps. My first attempt to do biotech at home is a total bust, and it cost me ...
- Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.on April 24, 2024 at 2:50 am
The success of Ozempic and Wegovy has also helped Novo Nordisk become a rock star for investors. Shares of the big drugmaker have skyrocketed nearly 240% over the last three years. Don't worry if you ...
via Bing News